Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

類似資料

• Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
  著者:: Moehler, Markus, 等
  出版事項: (2009)
• Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
  著者:: García-Alfonso, P, 等
  出版事項: (2010)
• Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
  著者:: Feliu, J, 等
  出版事項: (2010)
• Addition of Bevacizumab to XELOX Induction Therapy Plus Concomitant Capecitabine-Based Chemoradiotherapy in Magnetic Resonance Imaging–Defined Poor-Prognosis Locally Advanced Rectal Cancer: The AVACROSS Study
  著者:: Nogué, Miguel, 等
  出版事項: (2011)
• First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
  著者:: Díaz-Rubio, Eduardo, 等
  出版事項: (2012)